nach oben

Current Psychiatry Reports

Erschienen in:

01.11.2014 | Autism Spectrum Disorders (ES Brodkin, Section Editor)

Etiology of Autism Spectrum Disorder: A Genomics Perspective

verfasst von: John J. Connolly, Hakon Hakonarson

Erschienen in: Current Psychiatry Reports | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

In recent years, considerable progress has been made in understanding the genomic basis of autism spectrum disorder (ASD). Hundreds of variants have been proposed as predisposing to ASD, and the challenge now is to validate candidates and to understand how gene networks interact to produce ASD phenotypes. Genome-wide association and second-generation sequencing studies in particular have provided important indications about how to understand ASD on a molecular level, and we are beginning to see these experimental approaches translate into novel treatments and diagnostic tests. We review key studies in the field over the past five years and discuss some of the remaining technological and methodological challenges that remain.

Bailey A et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med. 1995;25:63–77.PubMedCrossRef

Lauritsen MB, Pedersen CB, Mortensen PB. Effects of familial risk factors and place of birth on the risk of autism: a nationwide register-based study. J Child Psychol Psychiatry. 2005;46:963–71. doi:10.1111/j.1469-7610.2004.00391.x.PubMedCrossRef

Sandin S et al. The familial risk of autism. JAMA. 2014;311:1770–7.PubMedCrossRef

St Pourcain B. Variability in the common genetic architecture of social-communication spectrum phenotypes during childhood and adolescence. Mol Autism. 2014;5:18.PubMedCrossRefPubMedCentral

Skuse DH. Rethinking the nature of genetic vulnerability to autistic spectrum disorders. Trends Genet. 2007;23:387–95. doi:10.1016/j.tig.2007.06.003.PubMedCrossRef

Hindorff L, MacArthur J, (2013). The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014 Jan;42(Database issue):D1001-6. doi:10.1093/nar/gkt1229.

Wang K et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature. 2009;459:528–33. doi:10.1038/nature07999.PubMedCrossRefPubMedCentral

Ma D et al. A genome-wide association study of autism reveals a common novel risk locus at 5p14.1. Ann Hum Genet. 2009;73:263–73. doi:10.1111/j.1469-1809.2009.00523.x.PubMedCrossRefPubMedCentral

St Pourcain B et al. Association between a high-risk autism locus on 5p14 and social communication spectrum phenotypes in the general population. Am J Psychiatry. 2010;167:1364–72. doi:10.1176/appi.ajp.2010.09121789.PubMedCrossRefPubMedCentral

10.••

Kerin T et al. A noncoding RNA antisense to moesin at 5p14.1 in autism. Sci Transl Med. 2012;4:128ra140. doi:10.1126/scitranslmed.3003479. This study provides important functional validation of the 5p14. 1 locus as an important correlate of ASD susceptibility. Furthermore, it highlights a limitation in DNA sequencing, which would have failed to identify the MSNP1AS pseudogene.CrossRef

11.

Arking DE et al. A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet. 2008;82:160–4. doi:10.1016/j.ajhg.2007.09.015.PubMedCrossRefPubMedCentral

12.

Alarcon M, Cantor RM, Liu J, Gilliam TC, Geschwind DH. Evidence for a language quantitative trait locus on chromosome 7q in multiplex autism families. Am J Hum Genet. 2002;70:60–71. doi:10.1086/338241.PubMedCrossRefPubMedCentral

13.

Vernes SC et al. A functional genetic link between distinct developmental language disorders. N Engl J Med. 2008;359:2337–45. doi:10.1056/NEJMoa0802828.PubMedCrossRefPubMedCentral

14.

Lai CS, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature. 2001;413:519–23. doi:10.1038/35097076.PubMedCrossRef

15.

Benayed R et al. Autism-associated haplotype affects the regulation of the homeobox gene, ENGRAILED 2. Biol Psychiatry. 2009;66:911–7. doi:10.1016/j.biopsych.2009.05.027.PubMedCrossRefPubMedCentral

16.

Wang L et al. Association of the ENGRAILED 2 (EN2) gene with autism in Chinese Han population. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:434–8. doi:10.1002/ajmg.b.30623.PubMedCrossRef

17.

Campbell DB et al. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A. 2006;103:16834–9. doi:10.1073/pnas.0605296103.PubMedCrossRefPubMedCentral

18.

Campbell DB, Li C, Sutcliffe JS, Persico AM, Levitt P. Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder. Autism Res. 2008;1:159–68. doi:10.1002/aur.27.PubMedCrossRefPubMedCentral

19.

Durand CM et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007;39:25–7.PubMedCrossRefPubMedCentral

20.

Moessner R et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet. 2007;81:1289–97. doi:10.1086/522590.PubMedCrossRefPubMedCentral

21.

Peça J et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature. 2011;472:437–42.PubMedCrossRefPubMedCentral

22.

McCauley J et al. Linkage and association analysis at the serotonin transporter (SLC6A4) locus in a rigid‐compulsive subset of autism. Am J Med Genet B Neuropsychiatr Genet. 2004;127:104–12.CrossRef

23.

Ro M et al. Association of the FGA and SLC6A4 Genes with autistic spectrum disorder in a Korean population. Neuropsychobiology. 2013;68:212–20.PubMedCrossRef

24.••

Klei L et al. Common genetic variants, acting additively, are a major source of risk for autism. Mol Autism. 2012;3(1):9. doi:10.1186/2040-2392-3-9. This study used genome-wide complex trait analysis (GCTA) to confirm the importance of common variants as ASD risk factors, supporting an additive model of ASD where many variants of small effect combine to increase susceptibility.PubMedCrossRefPubMedCentral

25.

Gaugler T et al. Most genetic risk for autism resides with common variation. Nat Genet. 2014;46:881–5.PubMedCrossRef

26.

Hoischen A, Krumm N, Eichler EE. Prioritization of neurodevelopmental disease genes by discovery of new mutations. Nat Neurosci. 2014;17:764–72.PubMedCrossRef

27.

Cross-Disorder Group of the Psychiatric Genomics Consortium et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45(9):984-94. doi:10.1038/ng.2711.

28.

Lupski JR. Genomic rearrangements and sporadic disease. Nat Genet. 2007;39:S43–7. doi:10.1038/ng2084.PubMedCrossRef

29.

Abecasis GR et al. A map of human genome variation from population-scale sequencing. Nature;467: 1061-1073, doi:10.1038/nature09534 (2010).

30.

Conrad DF et al. Origins and functional impact of copy number variation in the human genome. Nature. 2010;464:704–12. doi:10.1038/nature08516.PubMedCrossRefPubMedCentral

31.

Pang AW et al. Towards a comprehensive structural variation map of an individual human genome. Genome Biol. 2010;11:R52. doi:10.1186/gb-2010-11-5-r52.PubMedCrossRefPubMedCentral

32.

Sebat J et al. Strong association of de novo copy number mutations with autism. Science. 2007;316:445–9. doi:10.1126/science.1138659.PubMedCrossRefPubMedCentral

33.

Glessner JT, Connolly JJ, Hakonarson H. Rare genomic deletions and duplications and their role in neurodevelopmental disorders. Curr Top Behav Neurosci. 2012. doi:10.1007/7854_2011_179.PubMed

34.

Bucan M et al. Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet. 2009;5:e1000536. doi:10.1371/journal.pgen.1000536.PubMedCrossRefPubMedCentral

35.

Kim HG et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet. 2008;82:199–207. doi:10.1016/j.ajhg.2007.09.011.PubMedCrossRefPubMedCentral

36.

Guilmatre A et al. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch Gen Psychiatry. 2009;66:947–56. doi:10.1001/archgenpsychiatry.2009.80.PubMedCrossRefPubMedCentral

37.

Glessner JT et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature. 2009;459:569–73. doi:10.1038/nature07953.PubMedCrossRefPubMedCentral

38.

Yi JJ, Ehlers MD. Ubiquitin and protein turnover in synapse function. Neuron. 2005;47:629–32. doi:10.1016/j.neuron.2005.07.008.PubMedCrossRef

39.

Missler M, Südhof TC, Biederer T. Synaptic cell adhesion. Cold Spring Harb Perspect Biol. 2012;4:a005694.PubMedCrossRefPubMedCentral

40.

Pinto D, Marshall C, Feuk L, Scherer SW. Copy-number variation in control population cohorts. Hum Mol Genet. 2007;16 Spec No. 2:R168–73. doi:10.1093/hmg/ddm241.PubMedCrossRef

41.

Anney R et al. A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet. 2010;19:4072–82. doi:10.1093/hmg/ddq307.PubMedCrossRefPubMedCentral

42.•

Hadley D et al. The impact of the metabotropic glutamate receptor and other gene family interaction networks on autism. Nat Commun. 2014;5:4074. doi:10.1038/ncomms5074. To find potentially druggable genetic targets, this study compared family interaction networks (GFINs) in 6742 patients ASDs and 12,544 neurologically normal controls, identifying enrichment of structural defects in the metabotropic glutamate receptor GFIN, as well as MXD-MYC-MAX and calmodulin 1 (CALM1) GFINs.PubMedCrossRefPubMedCentral

43.

Povey S et al. The HUGO gene nomenclature committee (HGNC). Hum Genet. 2001;109:678–80.PubMedCrossRef

44.

Pinto D et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466:368–72. doi:10.1038/nature09146.PubMedCrossRefPubMedCentral

45.

Moreno-De-Luca D et al. Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts. Mol Psychiatry. 2012;18:1090–5.PubMedCrossRefPubMedCentral

46.

Gilman SR et al. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron. 2011;70:898–907. doi:10.1016/j.neuron.2011.05.021.PubMedCrossRefPubMedCentral

47.

Sachidanandam R et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928–33. doi:10.1038/35057149.PubMedCrossRef

48.

Sakai Y et al. Corticostriatal functional connectivity in non-medicated patients with obsessive-compulsive disorder. Eur Psychiatry. 2011;26:463–9.PubMedCrossRef

49.

Noh HJ et al. Network topologies and convergent aetiologies arising from deletions and duplications observed in individuals with autism. PLoS Genet. 2013;9:e1003523.PubMedCrossRefPubMedCentral

50.

Li H et al. The association analysis of RELN and GRM8 genes with autistic spectrum disorder in Chinese Han population. Am J Med Genet B Neuropsychiatr Genet. 2008;147:194–200.CrossRef

51.

Serajee F, Zhong H, Nabi R, Huq AM. The metabotropic glutamate receptor 8 gene at 7q31: partial duplication and possible association with autism. J Med Genet. 2003;40:e42.PubMedCrossRefPubMedCentral

52.

Cuscó I et al. Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. Hum Mol Genet. 2009;18:1795–804.PubMedCrossRefPubMedCentral

53.

Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011;480:63–8.PubMedCrossRefPubMedCentral

54.••

Iossifov I et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74:285–99. doi:10.1016/j.neuron.2012.04.009. Like several other studies in this review, Iossifov et al. use whole exome sequence to identify a range of mutations associated with ASD. Identification of the fragile X protein, FMRP, may have particularly important functional and translational consequences.PubMedCrossRefPubMedCentral

55.

Darnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci. 2013;16:1530–6.PubMedCrossRefPubMedCentral

56.

Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27:370–7. doi:10.1016/j.tins.2004.04.009.PubMedCrossRef

57.

Jacquemont S et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011. doi:10.1126/scitranslmed.3001708.PubMed

58.

Dolen G et al. Correction of fragile X syndrome in mice. Neuron. 2007;56:955–62.PubMedCrossRefPubMedCentral

59.

Richards RI et al. Fragile X syndrome: genetic localisation by linkage mapping of two microsatellite repeats FRAXAC1 and FRAXAC2 which immediately flank the fragile site. J Med Genet. 1991;28:818–23.PubMedCrossRefPubMedCentral

60.

Rogers SJ, Wehner DE, Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr. 2001;22:409–17.PubMedCrossRef

61.

Harris SW et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard. 2008;113:427–38.PubMedCrossRefPubMedCentral

62.

Curtis AR et al. X chromosome linkage studies in familial Rett syndrome. Hum Genet. 1993;90:551–5.PubMedCrossRef

63.

Ramocki MB et al. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann Neurol. 2009;66:771–82. doi:10.1002/ana.21715.PubMedCrossRefPubMedCentral

64.

Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004;113:e472–86.PubMedCrossRef

65.

Carney RM et al. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr Neurol. 2003;28:205–11.PubMedCrossRef

66.

Volkmar FR. Handbook of autism and pervasive developmental disorders. 3rd ed. New York: Wiley; 2005.CrossRef

67.

Li W et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol. 2005;15:1961–7. doi:10.1016/j.cub.2005.09.043.PubMedCrossRef

68.

Zafeiriou DI, Ververi A, Vargiami E. Childhood autism and associated comorbidities. Brain Dev. 2007;29:257–72. doi:10.1016/j.braindev.2006.09.003.PubMedCrossRef

69.

Schuurs-Hoeijmakers JH et al. Recurrent De Novo Mutations in <i> PACS1</i> cause defective cranial-neural-crest migration and define a recognizable intellectual-disability syndrome. Am J Hum Genet. 2012;91:1122–7.PubMedCrossRefPubMedCentral

70.

Rauch A et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet. 2012;380:1674–82.PubMedCrossRef

71.•

O'Roak BJ et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012. doi:10.1038/nature10989. The whole exome sequencing study showed that de novo germline mutations in coding regions are more prominent among males and found mutations in several existing ASD candidate genes.PubMedPubMedCentral

72.

Fischbach GD, Lord C. The Simons simplex collection: a resource for identification of autism genetic risk factors. Neuron. 2010;68:192–5. doi:10.1016/j.neuron.2010.10.006.PubMedCrossRef

73.

Hultman C, Sandin S, Levine S, Lichtenstein P, Reichenberg A. Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies. Mol Psychiatry. 2011;16:1203–12.PubMedCrossRef

74.

Malaspina D et al. Advancing paternal age and the risk of schizophrenia. Arch Gen Psychiatry. 2001;58:361–7.PubMedCrossRef

75.

McGrath JJ, et al. A Comprehensive Assessment of Parental Age and Psychiatric Disorders. JAMA psychiatry. 2014;71(3):301-9. doi: 10.1001/jamapsychiatry.2013.4081.

76.

Nishimura-Akiyoshi S, Niimi K, Nakashiba T, Itohara S. Axonal netrin-Gs transneuronally determine lamina-specific subdendritic segments. Proc Natl Acad Sci U S A. 2007;104:14801–6.PubMedCrossRefPubMedCentral

77.•

Neale BM et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012. doi:10.1038/nature11011. Whole exome sequencing study showed an association between de novo events and paternal age, as well as maternal age.

78.•

Sanders SJ et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012. doi:10.1038/nature10945. Whole exome sequencing study showing mutations in several ASD candidate genes. Of particular importance are two independent nonsense variants found to disrupt SCN2A.

79.

Weiss LA et al. Sodium channels SCN1A, SCN2A and SCN3A in familial autism. Mol Psychiatry. 2003;8:186–94.PubMedCrossRef

80.•

Jiang Y-h et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J Hum Genet. 2013;93:249–63. Whole genome sequencing study if 32 families identifies mutations in several existing ASD candidate loci.PubMedCrossRefPubMedCentral

81.

Kamiya K et al. A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline. J Neurosci. 2004;24:2690–8.PubMedCrossRef

82.

Ogiwara I et al. De novo mutations of voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies. Neurology. 2009;73:1046–53. doi:10.1212/WNL.0b013e3181b9cebc.PubMedCrossRefPubMedCentral

83.

Phenome E, Consortium EK. De novo mutations in epileptic encephalopathies. Nature. 2013. doi:10.1038/nature12439.

84.

de Ligt J et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012;367:1921–9.PubMedCrossRef

85.

Fromer M et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014. doi:10.1038/nature12929.PubMedCentral

86.

Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet. 2004;5:389–96.PubMedCrossRef

87.

Benjamini Y, Speed TP. Summarizing and correcting the GC content bias in high-throughput sequencing. Nucleic Acids Res. 2012;40:e72.PubMedCrossRefPubMedCentral

88.

Karakoc E et al. Detection of structural variants and indels within exome data. Nat Methods. 2012;9:176–8.CrossRef

89.

Glessner JT, Li J, Hakonarson H. ParseCNV integrative copy number variation association software with quality tracking. Nucleic Acids Res. 2013;41:e64. doi:10.1093/nar/gks1346.PubMedCrossRefPubMedCentral

90.

Bölte S. Is autism curable? Dev Med Child Neurol. 2014. doi:10.1111/dmcn.12495.PubMed

91.

Williams SC. Drugs targeting mGluR5 receptor offer 'fragile' hope for autism. Nat Med. 2012;18:840.PubMedCrossRef

92.

Pini G, et al. IGF1 as a potential treatment for Rett syndrome: safety assessment in six Rett patients. Autism research and treatment. 2012;679801. doi: 10.1155/2012/679801.

93.

Ehninger D et al. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008;14:843–8. doi:10.1038/nm1788.PubMedCrossRefPubMedCentral

94.

Ehninger D, Silva AJ. Rapamycin for treating tuberous sclerosis and autism spectrum disorders. Trends Mol Med. 2011;17:78–87.PubMedCrossRefPubMedCentral

95.

Silverman JL, Crawley JN. The promising trajectory of autism therapeutics discovery. Drug Discov Today. 2013. doi:10.1016/j.drudis.2013.12.007.PubMed

96.

Silverman JL et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med. 2012;4:131ra151. doi:10.1126/scitranslmed.3003501.CrossRef

97.

Delorme R et al. Progress toward treatments for synaptic defects in autism. Nat Med. 2013;19:685–94.PubMedCrossRef

Titel: Etiology of Autism Spectrum Disorder: A Genomics Perspective
verfasst von: John J. Connolly
Hakon Hakonarson
Publikationsdatum: 01.11.2014
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 11/2014
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-014-0501-9

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

Collaborative Care: Models for Treatment of Patients with Complex Medical-Psychiatric Conditions

Ovarian Hormones and Drug Abuse

Biomarkers in the Diagnosis of ADHD – Promising Directions

Psychosis and Seizure Disorder: Challenges in Diagnosis and Treatment